clinical trial · NCT06926621
A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
Vertex Pharmaceuticals Incorporated·phase2·enrolling by invitation·n = 44
Myotonic Dystrophy Type 1 (DM1)VX-670
brief summary
The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy Type I (DM1).
started
Apr 28, 2025
primary completion
Jan 30, 2029
completion
Jan 30, 2029
last updated
Feb 27, 2026
official title
An Open-label Extension Study Evaluating the Long-term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects With Myotonic Dystrophy Type I
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol